NFKB1 and acute myeloid leukemia: In AML, there is a solid connection of NFκB with malignant progression, but nevertheless, interventions based on inhibiting NFκB or its associated mediators such as bromodomain and extra-terminal domain (BET) protein BRD4 [109] have not proven clinically effective [110,111].